By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating from Havana, Cuba, by NewsRx correspondents, research stated, "The pIDKE2 plasmid is the main component of the CIGB's candidate vaccine against Hepatitis C virus (HVC), which is being used in HCV chronically-infected individuals during clinical trials phase 1 and 2. The designed downstream process of pIDKE2 plasmid produces up to 179 g/year. In order to conduct further improvements, modelling of the downstream process was performed."
Our news editors obtained a quote from the research from Polytechnic Institute, "A methodology based on process analysis tools, such as experimental design and modelling was established to identify factors with the highest influence on production cost and the amount of annual plasmid. Taking into account that the pIDKE2 downstream process designed is in its initial stages of development, CIM technology was evaluated as a new manufacturing process on lab scale. Purity and recovery of CIM technology was better than porous particle matrix, thus SuperPro Designer was used in order to simulate the purification process."
According to the news editors, the research concluded: "Cost efficiency optimization of the pIDKE2 downstream process was done with the simulation model."
For more information on this research see: Simulation for the recovery of plasmid for a DNA vaccine. Biochemical Engineering Journal, 2013;80():14-18. Biochemical Engineering Journal can be contacted at: Elsevier Science Sa, PO Box 564, 1001 Lausanne, Switzerland. (Elsevier - www.elsevier.com; Biochemical Engineering Journal - www.elsevier.com/wps/product/cws_home/600804)
The news editors report that additional information may be obtained by contacting M. Limonta, Higher Polytechnic Inst Jose Antonio Echeverria, Havana, Cuba. Additional authors for this research include N.L. Krajnc, U. Vidic and L. Zumalacarregui (see also Biotechnology).
Keywords for this news article include: Cuba, Biotechnology, Havana, Viral DNA, DNA Vaccines, Synthetic Vaccines, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC